TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
Open Access
- 1 January 2001
- Vol. 3 (6) , 535-546
- https://doi.org/10.1038/sj.neo.7900203
Abstract
No abstract availableKeywords
This publication has 138 references indexed in Scilit:
- TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2Oncogene, 2001
- Overexpression of Bcl2 Blocks TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Human Lung Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Bcl-2–Mediated Drug ResistanceThe Journal of Experimental Medicine, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998
- The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death DomainImmunity, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996
- Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genesNature, 1996